Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
peptide |
| gptkbp:administeredBy |
treatment of blood disorders
|
| gptkbp:alternativeName |
PTG-300
|
| gptkbp:CASNumber |
2228192-82-6
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Protagonist_Therapeutics
|
| gptkbp:hasMolecularFormula |
C114H171N33O34S2
|
| gptkbp:hasUNII |
1Q1K1J8J1N
|
| https://www.w3.org/2000/01/rdf-schema#label |
rusfertide
|
| gptkbp:indication |
gptkb:polycythemia_vera
|
| gptkbp:isInvestigational |
true
|
| gptkbp:mechanismOfAction |
hepcidin mimetic
|
| gptkbp:reduces |
gptkb:hematocrit
|
| gptkbp:regulates |
serum iron levels
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
iron homeostasis
|
| gptkbp:bfsParent |
gptkb:Protagonist_Therapeutics
|
| gptkbp:bfsLayer |
8
|